EASTERN COOPERATIVE ONCOLOGY GROUP

描述(由申请人提供)：本申请是代表AECC提交的，目的是作为东部合作肿瘤学小组(ECOG)的主要机构成员，通过U10机制请求继续提供资金。爱因斯坦的教职员工在ECOG中扮演着关键的科学和行政领导角色，并积累了大量的少数族裔主题和女性。爱因斯坦癌症中心是NCI指定的癌症中心，自1971年以来一直得到资助，目前资助到2012年7月(P30 CA13330)。在截至2009年4月30日的最后五年资助期内，爱因斯坦及其附属机构通过ECOG机制累计了604名患者参加癌症临床试验，其中包括主要机构的229项治疗应计费用。此外，在主要院校招收的所有科目中有4%是少数民族科目。爱因斯坦的教职员工在乳房(J.Sparano)、肺(R.Perez-Soler)、白血病(R.Gallagher，A.Verma)、头/颈(M.Haigentz)、胸外科(S.Keller)和Gl(L.Rajdev)委员会提供了科学领导。爱因斯坦研究人员撰写或合著了28篇与ECOG研究相关的手稿和69篇摘要，其中包括影响可手术乳腺癌护理标准的出版物(E1199-NEJM，2008)，并影响了正在进行的E5103乳腺癌辅助剂试验的标准辅助化疗的选择。此外，在大型科学会议上的演讲对乳腺癌生物标记物的开发做出了贡献，包括在2008年ASCO乳腺癌研讨会、2009年圣安东尼奥乳腺癌研讨会和2009年ASCO会议上的口头演讲。此外，爱因斯坦的APL核心实验室(R.Gallagher)支持ECOG的翻译研究，爱因斯坦表观基因组学中心(J.Gally)将在下一个资助期发挥重要作用。这项申请的首席研究员(J.Sparano)还在ECOG担任执行委员会成员、疾病和形态导向研究副主席、乳房委员会副主席、TAILORx研究主席以及ECOG年度青年研究人员研讨会的项目主席。最后，最近招聘的Steven Libuti博士将有助于扩大外科肿瘤学项目，并将更多的患者吸引到爱因斯坦，而Bruce Rapkin博士将通过将临床试验整合到标准护理的范围来提高收益。此外，Perez-Soler博士最近获得了K12 Calabresi补助金，这笔赠款将支持招募更多从事临床研究的初级肿瘤学教员。 相关性：为实现东部合作肿瘤学小组(ECOG)的使命提供关键的临床科学领导和资源，该使命通过改善早期和晚期癌症患者的管理来减少癌症相关的发病率和死亡率。

DESCRIPTION (provided by applicant): This application is submitted on behalf of the AECC in order to request continued funding via the U10 mechanism as a main institutional member of the Eastern Cooperative Oncology Group (ECOG). Einstein faculty members play key scientific and administrative leadership roles in ECOG, and accrue a large number of minority subjects and women. The Einstein Cancer Center is an NCI-designated Cancer Center that has been continuously funded since 1971, and is currently funded until July 2012 (P30 CA13330). During the last five year funding period ending 4/30/09, Einstein and its affiliates accrued a total of 604 patients into cancer clinical trials via the ECOG mechanism, including 229 therapeutic accruals from the main institution. Moreover, 64% of all subjects enrolled at the main institution were minority subjects. Einstein faculty members have provided scientific leadership in the breast (J. Sparano), lung (R. Perez-Soler), leukemia (R. Gallagher, A. Verma), head/neck (M. Haigentz), thoracic surgery (S. Keller), and Gl (L. Rajdev) committees. Einstein-affiliated investigators have authored or co-authored 28 manuscripts and 69 abstracts related to ECOG studies, including publications that have influenced the standard of care for operable breast cancer (E1199 - NEJM, 2008) and influenced choice of the standard adjuvant chemotherapy for the ongoing adjuvant E5103 breast cancer trial. In addition, presentations at major scientific meetings have contributed to biomarker development in breast cancer, including oral presentations at the 2008 ASCO Breast Cancer Symposium, 2009 San Antonio Breast Cancer Symposium, and 2009 ASCO meeting. Furthermore, the APL Core Laboratory at Einstein (R. Gallagher) has supported ECOG's translational research, and the Einstein Center for Epigenomics (J. Greally) is positioned to play a major role in the next funding period. The principal investigator of this application (J. Sparano) also pays a key administrative role in ECOG as an Executive Committee member, Associate Chair for Disease and Modality Oriented Research, Vice- Chair of the Breast Committee, TAILORx study chair, and program chair for the annual ECOG Young Investigator's Symposium. Finally, the recent recruitment Dr. Steven Libutti will serve to expand the surgical oncology program and draw more patients to Einstein, and of Dr. Bruce Rapkin will serve to enhance accrual by integrating clinical trials into the spectrum of standard care. In addition, Dr. Perez-Soler was recently awarded a K12 Calabresi grant which will support the recruitment of additional junior medical oncology faculty members engaged in clinical research. RELEVANCE: To provide clinical scientific leadership and resources critical for achieving the Eastern Cooperative Oncology Group (ECOG) mission of reducing cancer-related morbidity and mortality by improving the management of early- and advanced-stage carreer.